Drug Profile


Alternative Names: NG 273

Latest Information Update: 06 Jul 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurogen Corporation
  • Developer Ligand Pharmaceuticals
  • Class Imidazoles; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action GABA A alpha 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Insomnia; Schizophrenia

Most Recent Events

  • 06 Jul 2010 Development discontinued during 2008
  • 14 Jul 2008 Suspended - Phase-II/III for Insomnia in USA (PO)
  • 12 Jun 2008 Final efficacy data from two phase II trials in Insomnia presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top